Clinical Oncology Next-generation Sequencing Market

Clinical Oncology Next-generation Sequencing Market: Launch of Low-cost Sequencing Platforms to Accelerate Adoption: Global Industry Analysis 2014-2018 and Opportunity Assessment 2019-2029

Clinical Oncology Next-Generation Sequencing Market - Key Research Findings

  1. Global clinical oncology next-generation sequencing market size in 2018- Over US$ 200 Mn

  2. The clinical oncology next-generation sequencing market is expected to observe a CAGR of 17.0% over 2019-2029.

  3. North America and Europe are expected to remain the largest regional markets for clinical oncology next-generation sequencing

    • The presence of well-established healthcare infrastructure in the U.S. is one of the major factors contributing to the growth of the clinical oncology next-generation sequencing market.

  4. North America is expected to exhibit a high growth potential for the clinical oncology next-generation sequencing market

    • Increasing healthcare awareness is expected to increase the boost the clinical oncology next-generation sequencing market.

Top 3 Factors Shaping the Clinical Oncology Next-Generation Sequencing Market

  • Increasing prevalence of cancers

    Increasing prevalence of cancer is a major factor responsible for the growth of the clinical oncology next-generation sequencing market. Increasing biomedical research using clinical oncology next-generation sequencing is expected to create a conducive atmosphere for the growth of the clinical oncology next-generation sequencing market in the near future. According to WHO, cancer is the second leading cause of death globally, and was responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths are caused by cancer. By 2030, the global burden is expected to grow to 21.7 million new cancer cases and 13 million cancer deaths.

  • Increasing government funding for life science projects is expected to boost the clinical oncology next-generation sequencing market

    Government funding for life science research is expected to result in the availability of funding for the undertaking of various clinical oncology next-generation sequencing projects, as well as for the employment of the required personnel. This is expected to contribute to the growth of the clinical oncology next-generation sequencing market.

    The various sources of research and development spending include governments, private funding, and commercial organizations. Different life science projects have been undertaken, which has resulted in the employment of various personnel, and this is likely to fuel the growth of the clinical oncology next-generation sequencing market.

  • Declining prices of sequencing are highly likely to contribute to the growth of the clinical oncology next-generation sequencing market

    The characteristic features of clinical oncology next-generation sequencing technology are implicated widely in research and academic institutes. Clinical oncology next-generation sequencing techniques offer a high percentage of reads and cost-effectiveness per read. This has been possible due to the launch of low-cost sequencing platforms in the market. This can increase the overall growth of the clinical oncology next-generation sequencing market. Various market players, such as Roche and Illumina, have introduced sequencing techniques that have reduced the cost of clinical oncology next-generation sequencing.

Clinical Oncology Next-Generation Sequencing Market Structure Analysis

  • In the global clinical oncology next-generation sequencing market, tier 1 companies hold a revenue share of more than 60%.
  • Most of the key players in the clinical oncology next-generation sequencing market focus on developing innovative products. They also focus on partnerships and collaborations to expand their product portfolio.

Clinical Oncology Next-Generation Sequencing – A method for cancer profiling

The demand of clinical oncology next-generation sequencing devices is expected to increase due to the increasing prevalence of cancer and rise in cancer diagnostics. The manufacturers of clinical oncology next-generation sequencing devices are majorly focusing on the partnerships and collaborations, especially international collaborations.

Market Set to Grow 4.9x between 2019 and 2029

The clinical oncology next-generation sequencing market is likely to witness steady growth over the course of the forecast period. Increasing prevalence of cancer, increasing government funding for life science projects and the declining prices of sequencing are some of the major factors driving the growth of the clinical oncology next-generation sequencing market.

Emerging Countries Promise New Growth Opportunities

North America is expected to contribute the highest revenue share in the global clinical oncology next-generation sequencing market in 2019. However, healthy growth is expected in developing countries, especially China, India, and South Korea. Among the emerging countries, China is likely to present sustained opportunities of growth for stakeholders in the clinical oncology next-generation sequencing market.

The Broader Perspective

Stakeholders in the clinical oncology next-generation sequencing market are adopting new technologies for cancer profiling and molecular disgnostics. The key players of the clinical oncology next-generation sequencing market are mainly focusing on mergers and acquisitions, especially on international collaborations. This has helped developing countries provide support to establish centers of excellence. With public funding, equipment availability, and training, these collaborations are likely to be fruitful.

CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET TAXONOMY

The global clinical oncology next generation sequencing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach in front of the reader.

By Product

  • Sequencing Platforms
  • Sequencing Products
  • Kits and Reagents
  • Services

By Technology

  • Ion Semiconductor Sequencing
  • Pyro-Sequencing
  • Synthesis Sequencing (SBS)
  • Real Time Sequencing (SMRT)
  • Ligation Sequencing
  • Reversible Dye Termination Sequencing
  • Nano-Pore Sequencing

By Application

  • Whole Tumor Genome Sequencing
  • Whole Tumor Exome Sequencing
  • Targeted Tumor Genome Profiling
  • Tumor Transcriptome Sequencing
  • Tumor-normal Comparisons
  • Others

By End User

  • Hospital Laboratories
  • Clinical Research Organizations
  • Diagnostic Laboratories
  • Others

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Need specific information?

In the news

How Businesses Can Utilize Market Research to Create Reactive, Recession-proof Strategies for Survival

by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights

Our Clients

View Our Reports from Healthcare

View Reports

Recommendations

Clinical Oncology Next-generation Sequencing Market